ArchivesMagazine - 20 Nov 2014Premaitha eyes genetic test Pre-natal screening company is waiting on regulatory approval 20 November 2014|Feature Issue: 20 Nov 2014 - Page 38 < Best & Worst Performing Small Caps Table R&D capitalising controversy > Issue: 20 Nov 2014 - Page 38 | Contents Next: R&D capitalising controversy Previous: Best & Worst Performing Small Caps Table Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Mark Dunne Issue Contents Chartist British brands in focus Feature Best & Worst Performing Small Caps Table The Best & Worst Performers: FTSE 350, Global Market, Commodities, Forex, Sovereign Yields Director Dealings: Top buys and sells Preview: Netcall Flybe cleared for take-off R&D capitalising controversy Euro sparks into life Keep a watching eye Under the microscope Sterling on the slide Strat Aero’s drone push Premaitha eyes genetic test New ventures, new horizons Creston’s joined up thinking Sleep at night investments Premier's balancing act Charge ahead Funds Profit from mighty oaks News News in brief: Tracsis, Quintain, Salamander, IG, Haliburton, Volex, Red24, James Fisher Reckitt to float drugs arm Go with the Scapa flow Don’t bank on Virgin Money House prices on shaky ground Carnival’s slick move India’s corporate boost Plays Plays update: Prudential Plays update: Telit Communications Plays update: Diploma Plus500 powers on Plays update: Redcentric Cambria is in top gear Sector Reports Still on the defensive Under The Bonnet Pay closer attention